CN120112527A - 自分泌运动因子抑制剂cudetaxestat的多晶型形式和盐形式 - Google Patents

自分泌运动因子抑制剂cudetaxestat的多晶型形式和盐形式 Download PDF

Info

Publication number
CN120112527A
CN120112527A CN202380049621.6A CN202380049621A CN120112527A CN 120112527 A CN120112527 A CN 120112527A CN 202380049621 A CN202380049621 A CN 202380049621A CN 120112527 A CN120112527 A CN 120112527A
Authority
CN
China
Prior art keywords
degrees
crystalline form
compound
composition
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380049621.6A
Other languages
English (en)
Chinese (zh)
Inventor
普拉巴·易卜拉欣
杰克·钟-杰·林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Difang Intellectual Property Acquisition Co ltd
Original Assignee
Difang Intellectual Property Acquisition Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Difang Intellectual Property Acquisition Co ltd filed Critical Difang Intellectual Property Acquisition Co ltd
Publication of CN120112527A publication Critical patent/CN120112527A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380049621.6A 2022-05-03 2023-04-28 自分泌运动因子抑制剂cudetaxestat的多晶型形式和盐形式 Pending CN120112527A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263364065P 2022-05-03 2022-05-03
US63/364,065 2022-05-03
PCT/US2023/020428 WO2023215196A1 (en) 2022-05-03 2023-04-28 Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat

Publications (1)

Publication Number Publication Date
CN120112527A true CN120112527A (zh) 2025-06-06

Family

ID=88646878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380049621.6A Pending CN120112527A (zh) 2022-05-03 2023-04-28 自分泌运动因子抑制剂cudetaxestat的多晶型形式和盐形式

Country Status (7)

Country Link
US (1) US20250282759A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519253A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025516335A (cg-RX-API-DMAC7.html)
CN (1) CN120112527A (cg-RX-API-DMAC7.html)
AU (1) AU2023265017A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251769A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023215196A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160654A1 (es) * 2013-11-22 2016-07-15 Pharmakea Inc Compuestos de inhibidor de autotaxina
CN116059203A (zh) * 2015-05-27 2023-05-05 赛博治疗有限责任公司 自分泌运动因子抑制剂及其用途

Also Published As

Publication number Publication date
WO2023215196A1 (en) 2023-11-09
US20250282759A1 (en) 2025-09-11
EP4519253A4 (en) 2026-06-10
JP2025516335A (ja) 2025-05-27
EP4519253A1 (en) 2025-03-12
CA3251769A1 (en) 2023-11-09
AU2023265017A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
US12458627B2 (en) Autotaxin inhibitors and uses thereof
CN107698569B (zh) 作为jak抑制剂的联吡唑衍生物
TWI433677B (zh) 雜環化合物及其用途
JPWO2021132422A1 (ja) ピリダジニルチアアゾールカルボキシアミド化合物
MX2012009541A (es) Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa.
CN110914253B (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
CN105246887B (zh) 香豆素衍生物以及用于治疗过度增生性疾病的方法
JP2022530967A (ja) 多形化合物およびその使用
KR20140145157A (ko) 상피 성장 인자 수용체 키나제 억제제의 고체 형태
US20250282759A1 (en) Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat
US12390451B2 (en) Small molecule inhibitor of the JAK family of kinases
JP2025526320A (ja) 治療用の化合物、製剤、およびその使用
RU2782375C2 (ru) Новые соединения и их фармацевтические композиции для лечения заболеваний
HK40077153A (en) Autotaxin inhibitors and uses thereof
EA037347B1 (ru) Низкомолекулярные ингибиторы киназ семейства jak

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination